Ausgabe 2/2016
Inhalt (20 Artikel)
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
Elisabeth Sulaica, Tiffany Han, Weiqun Wang, Raksha Bhat, Meghana V. Trivedi, Polly Niravath
Germline RECQL mutations in high risk Chinese breast cancer patients
Ava Kwong, Vivian Y. Shin, Isabella W. Y. Cheuk, Jiawei Chen, Chun H. Au, Dona N. Ho, Tsun L. Chan, Edmond S. K. Ma, Mohammad R. Akbari, Steven A. Narod
Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1
Cecilia L. Speyer, Mahdy A. Nassar, Ali H. Hachem, Miriam A. Bukhsh, Waris S. Jafry, Rafa M. Khansa, David H. Gorski
The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema
Fangdi Sun, Melissa N. Skolny, Meyha N. Swaroop, Bhupendra Rawal, Paul J. Catalano, Cheryl L. Brunelle, Cynthia L. Miller, Alphonse G. Taghian
Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells
Randi Wise, Sara Duhachek-Muggy, Yue Qi, Michal Zolkiewski, Anna Zolkiewska
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Luca Gelsomino, Guowei Gu, Yassine Rechoum, Amanda R. Beyer, Sasha M. Pejerrey, Anna Tsimelzon, Tao Wang, Kenneth Huffman, Andrew Ludlow, Sebastiano Andò, Suzanne A. W. Fuqua
A novel subtype classification and risk of breast cancer by histone modification profiling
Xiaohua Chen, Hanyang Hu, Lin He, Xueyuan Yu, Xiangyu Liu, Rong Zhong, Maoguo Shu
The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies
Andreas Karakatsanis, Peer Michael Christiansen, Lone Fischer, Christina Hedin, Lida Pistioli, Malin Sund, Nils Ryegaard Rasmussen, Hjørdis Jørnsgård, Daniel Tegnelius, Staffan Eriksson, Kosmas Daskalakis, Fredrik Wärnberg, Christos J. Markopoulos, Leif Bergkvist
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Kenichi Inoue, Tsuyoshi Saito, Katsuhiko Okubo, Kei Kimizuka, Hirofumi Yamada, Takashi Sakurai, Kazuo Ishizuna, Satoshi Hata, Toshihiro Kai, Masafumi Kurosumi
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
William Jacot, Elvire Pons, Jean-Sébastien Frenel, Séverine Guiu, Christelle Levy, Pierre Etienne Heudel, Thomas Bachelot, Véronique D’Hondt, Amélie Darlix, Nelly Firmin, Gilles Romieu, Simon Thezenas, Florence Dalenc
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
Dana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, Yael Laitman, Shani Paluch-Shimon, Rita Schmutzler, Kerstin Rhiem, Jenny Lester, Beth Y. Karlan, Christian F. Singer, Tom Van Maerken, Kathleen Claes, Joan Brunet, Angel Izquierdo, Alex Teulé, Jong Won Lee, Sung-Won Kim, Banu Arun, Anna Jakubowska, Jan Lubinski, Katherine Tucker, Nicola K. Poplawski, Liliana Varesco, Luigina Ada Bonelli, Saundra S. Buys, Gillian Mitchell, Marc Tischkowitz, Anne-Marie Gerdes, Caroline Seynaeve, Mark Robson, Ava Kwong, Nadine Tung, Nalven Tessa, Susan M. Domchek, Andrew K. Godwin, Johanna Rantala, Brita Arver, Eitan Friedman
Plasma S100P level as a novel prognostic marker of metastatic breast cancer
Cike Peng, Hongda Chen, Markus Wallwiener, Caroline Modugno, Katarina Cuk, Dharanija Madhavan, Andreas Trumpp, Jörg Heil, Frederik Marmé, Juliane Nees, Sabine Riethdorf, Sarah Schott, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, Rongxi Yang, Barbara Burwinkel
Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer
Aron S. Rosenstock, Xiudong Lei, Debu Tripathy, Gabriel N. Hortobagyi, Sharon H. Giordano, Mariana Chavez-MacGregor
Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy
Annette M. Molinaro, Jennette D. Sison, Britt-Marie Ljung, Thea D. Tlsty, Karla Kerlikowske
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
Sara Bustreo, Simona Osella-Abate, Paola Cassoni, Michela Donadio, Mario Airoldi, Fulvia Pedani, Mauro Papotti, Anna Sapino, Isabella Castellano
Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer
Jinhai Huo, Benjamin D. Smith, Sharon H. Giordano, Gregory P. Reece, Ya-Chen Tina Shih
Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy
Cynthia Villarreal-Garza, Juan Enrique Bargallo-Rocha, Enrique Soto-Perez-de-Celis, Federico Lasa-Gonsebatt, Claudia Arce-Salinas, Fernando Lara-Medina, Nancy Reynoso-Noverón, Juan Matus-Santos, Paula Cabrera, Alberto Alvarado-Miranda, Alejandro Mohar
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia
Viswanath Reddy Belum, Giselle de Barros Silva, Mariana Tosello Laloni, Kathryn Ciccolini, Shari B. Goldfarb, Larry Norton, Nancy T. Sklarin, Mario E. Lacouture
Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom
Nina Schmidt, Louis Jacob, Robert Coleman, Karel Kostev, Peyman Hadji
Erratum: Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)
Alice C. Shapiro, Susan A. Adlis, Kim Robien, Mark N. Kirstein, Shuang Liang, Sara A. Richter, Rachel E. Lerner